Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06385522
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-26
First Post:
2024-04-23
Brief Title:
A Clinical Trial in Adults With Non-Hodgkin Lymphoma NHL With a Particular Emphasis on Cutaneous T Cell Lymphoma CTCL Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Sponsor:
Boston Immune Technologies and Therapeutics
Organization:
Boston Immune Technologies and Therapeutics
Organization Data
Organization:
Boston Immune Technologies and Therapeutics
Class:
INDUSTRY
Study ID:
BITR2101-C-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boston Immune Technologies and Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None